All type of patients: 2 trials - VALIANT (valsartan alone) - VALIANT (valsartan+capropril)
| Valsartan vs Captopril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | death from cardiovascular causes or hospitalization for cardiovascular causes | no data | | Cardiovascular death | 1.00 [0.90 1.11] | p=1.00 | 0 | 9818 | 1 | VALIANT (valsartan alone), | | hospitalisation for heart failure | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | 1.02 [0.93 1.13] | p=1.00 | 0 | 9818 | 1 | VALIANT (valsartan alone), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| Valsartan+ACE inhibitor vs ACE inhibitor only | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | death from cardiovascular causes or hospitalization for cardiovascular causes | no data | | Cardiovascular death | 1.00 [0.90 1.11] | p=1.00 | 0 | 9794 | 1 | VALIANT (valsartan+capropril), | | hospitalisation for heart failure | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | 0.99 [0.89 1.09] | p=1.00 | 0 | 9794 | 1 | VALIANT (valsartan+capropril), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patient with history of atrial fibrillation: 1 trials - GISSI-AF (Disertori)
| valsartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Vascular death | no data | | atrial fibrillation recurrence | 0.99 [0.80 1.21] | p=1.00 | 0 | 1442 | 1 | GISSI-AF (Disertori), | | more than one AF recurrence | 0.96 [0.76 1.21] | p=1.00 | 0 | 1442 | 1 | GISSI-AF (Disertori), | | Vascular events | no data | | hospitalisation for heart failure | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients : 1 trials - NAVIGATOR valsartan
| valsartan vs placebo | No demonstrated result suggested Diabetes by 10% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | no data | | cardiovascular events | 0.98 [0.87 1.10] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | Cardiovascular death | 1.11 [0.86 1.44] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | myocardial infarction (fatal and non fatal) | 1.00 [0.78 1.26] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | stroke (fatal and non fatal) | 0.80 [0.62 1.04] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | cardiovascular death, MI, stroke | no data | | Diabetes | 0.90 [0.82 0.98] | p=0.04 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | hospitalisation for heart failure | 0.98 [0.73 1.31] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | All cause death | 0.91 [0.77 1.07] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
People with impaired glucose tolerance: 1 trials - NAVIGATOR valsartan
| valsartan vs placebo | No demonstrated result suggested Diabetes by 10% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | no data | | cardiovascular events | 0.98 [0.87 1.10] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | Cardiovascular death | 1.11 [0.86 1.44] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | myocardial infarction (fatal and non fatal) | 1.00 [0.78 1.26] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | stroke (fatal and non fatal) | 0.80 [0.62 1.04] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | cardiovascular death, MI, stroke | no data | | Diabetes | 0.90 [0.82 0.98] | p=0.04 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | hospitalisation for heart failure | 0.98 [0.73 1.31] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | All cause death | 0.91 [0.77 1.07] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 6 trials - HEAVEN - Mazayev et al. (vs placebo) - V-HeFT - Val-HeFT - Mazayev et al. (vs lisinopril - VALIDD
| valsartan vs enalapril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | 0.55 [0.19 1.59] | p=1.00 | 0 | 141 | 1 | HEAVEN, | | All cause death | 0.20 [0.02 1.78] | p=1.00 | 0 | 141 | 1 | HEAVEN, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| valsartan vs Lisinopril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | 0.78 [0.25 2.40] | p=1.00 | 0 | 90 | 1 | Mazayev et al. (vs lisinopril, | | All cause death | 0.20 [0.00 10.49] | p=1.00 | 0 | 90 | 1 | Mazayev et al. (vs lisinopril, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| valsartan vs no valsartan | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| valsartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | 1.52 [0.59 3.92] | p=1.00 | 0 | 101 | 1 | Mazayev et al. (vs placebo), | | All cause death | 0.35 [0.02 5.75] | p=1.00 | 0 | 101 | 1 | Mazayev et al. (vs placebo), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| valsartan+ACE inhibitor vs ACE inhibitor only | No demonstrated result by 401% (harmful effect) Adverse events by 46% (harmful effect) suggested hospitalisation for heart failure by 24% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | 0.76 [0.65 0.88] | p=0.04 | 0 | 5010 | 1 | Val-HeFT, | | Hospitalization for any reason | no data | | 5.01 [1.91 13.16] | p=0.04 | 0 | 4727 | 2 | V-HeFT,Val-HeFT, | | Hyperkalaemia | 4.58 [0.24 88.29] | p=1.00 | 0 | 83 | 1 | V-HeFT, | | Cough | no data | | Hypotension | 1.70 [0.97 2.98] | p=1.00 | 0 | 4727 | 2 | V-HeFT,Val-HeFT, | | angiodema | no data | | Adverse events | 1.46 [1.18 1.80] | p=0.04 | 0 | 4644 | 1 | Val-HeFT, | | All cause death | 1.02 [0.89 1.17] | p=1.00 | 0 | 5093 | 2 | V-HeFT,Val-HeFT, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients already receiving ACE inhibitor: 3 trials - HEAVEN - V-HeFT - Val-HeFT
| valsartan vs enalapril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | 0.55 [0.19 1.59] | p=1.00 | 0 | 141 | 1 | HEAVEN, | | All cause death | 0.20 [0.02 1.78] | p=1.00 | 0 | 141 | 1 | HEAVEN, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| valsartan+ACE inhibitor vs ACE inhibitor only | No demonstrated result by 401% (harmful effect) Adverse events by 46% (harmful effect) suggested hospitalisation for heart failure by 24% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | 0.76 [0.65 0.88] | p=0.04 | 0 | 5010 | 1 | Val-HeFT, | | Hospitalization for any reason | no data | | 5.01 [1.91 13.16] | p=0.04 | 0 | 4727 | 2 | V-HeFT,Val-HeFT, | | Hyperkalaemia | 4.58 [0.24 88.29] | p=1.00 | 0 | 83 | 1 | V-HeFT, | | Cough | no data | | Hypotension | 1.70 [0.97 2.98] | p=1.00 | 0 | 4727 | 2 | V-HeFT,Val-HeFT, | | angiodema | no data | | Adverse events | 1.46 [1.18 1.80] | p=0.04 | 0 | 4644 | 1 | Val-HeFT, | | All cause death | 1.02 [0.89 1.17] | p=1.00 | 0 | 5093 | 2 | V-HeFT,Val-HeFT, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients previously untreated with ACE inhibitors: 2 trials - Mazayev et al. (vs placebo) - Mazayev et al. (vs lisinopril
| valsartan vs Lisinopril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | 0.78 [0.25 2.40] | p=1.00 | 0 | 90 | 1 | Mazayev et al. (vs lisinopril, | | All cause death | 0.20 [0.00 10.49] | p=1.00 | 0 | 90 | 1 | Mazayev et al. (vs lisinopril, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| valsartan vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | 1.52 [0.59 3.92] | p=1.00 | 0 | 101 | 1 | Mazayev et al. (vs placebo), | | All cause death | 0.35 [0.02 5.75] | p=1.00 | 0 | 101 | 1 | Mazayev et al. (vs placebo), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with preserved-LVEF heart failure : 1 trials - VALIDD
| valsartan vs no valsartan | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | no data | | Death from any cause or hospitalization for any reason | no data | | Cardiovascular death or hospital admission for CHF | no data | | death or cardiovascular hospitalization | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | Hospitalization for any reason | no data | | no data | | Hyperkalaemia | no data | | Cough | no data | | Hypotension | no data | | angiodema | no data | | Adverse events | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All diseases requiring ACEi (HF, CHD, HT,...): 1 trials - VALIANT/Val
| Valsartan vs Captopril | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | 1.00 [0.90 1.11] | p=1.00 | 0 | 9818 | 1 | VALIANT/Val, | | myocardial infarction (fatal and non fatal) | 1.00 [0.90 1.11] | p=1.00 | 0 | 9818 | 1 | VALIANT/Val, | | stroke (fatal and non fatal) | 0.85 [0.70 1.05] | p=1.00 | 0 | 9818 | 1 | VALIANT/Val, | | All cause death | 1.02 [0.93 1.13] | p=1.00 | 0 | 9818 | 1 | VALIANT/Val, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - NAVIGATOR valsartan
| valsartan vs placebo | No demonstrated result suggested Diabetes by 10% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | no data | | cardiovascular events | 0.98 [0.87 1.10] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | Cardiovascular death | 1.11 [0.86 1.44] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | myocardial infarction (fatal and non fatal) | 1.00 [0.78 1.26] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | stroke (fatal and non fatal) | 0.80 [0.62 1.04] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | cardiovascular death, MI, stroke | no data | | Diabetes | 0.90 [0.82 0.98] | p=0.04 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | hospitalisation for heart failure | 0.98 [0.73 1.31] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, | | All cause death | 0.91 [0.77 1.07] | p=1.00 | 0 | 9306 | 1 | NAVIGATOR valsartan, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
